Marcelle I Cedars

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8944178/publications.pdf

Version: 2024-02-01

95 papers 2,830 citations

196777 29 h-index 232693 48 g-index

96 all docs 96 docs citations

96 times ranked 3692 citing authors

#	Article	IF	CITATIONS
1	Untangling the Influence of Sex Hormones on Nonalcoholic Fatty Liver Disease in Women. Clinical Gastroenterology and Hepatology, 2022, 20, 1887-1888.	2.4	1
2	COVID-19 vaccination patterns and attitudes among American pregnant individuals. American Journal of Obstetrics & Covideration (2018) amp; Gynecology MFM, 2022, 4, 100507.	1.3	14
3	Promotion of gender equity in obstetrics and gynecology: principles and practices for academic leaders. American Journal of Obstetrics and Gynecology, 2022, 226, 163-168.	0.7	3
4	Effects of preconception lifestyle intervention in infertile women with obesity: The FIT-PLESE randomized controlled trial. PLoS Medicine, 2022, 19, e1003883.	3.9	34
5	Evaluation of Female Fertility—AMH and Ovarian Reserve Testing. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1510-1519.	1.8	40
6	Decision regret after failed autologous inÂvitro fertilization in women ≥42 years of age. Fertility and Sterility, 2022, 117, 1301-1308.	0.5	3
7	Managing poor ovarian response in the patient with diminished ovarian reserve. Fertility and Sterility, 2022, 117, 655-656.	0.5	5
8	Is it time to revisit Rotterdam?. Fertility and Sterility, 2022, 117, 696-697.	0.5	2
9	Microfluidic preparation of spermatozoa for ICSI produces similar embryo quality to density-gradient centrifugation: a pragmatic, randomized controlled trial. Human Reproduction, 2022, 37, 1406-1413.	0.4	10
10	Testosterone is Associated With Nonalcoholic Steatohepatitis and Fibrosis in Premenopausal Women With NAFLD. Clinical Gastroenterology and Hepatology, 2021, 19, 1267-1274.e1.	2.4	25
11	Highly elevated level of antim \tilde{A}^{1} /llerian hormone associated with preterm delivery in polycystic ovary syndrome patients who underwent ovulation induction. Fertility and Sterility, 2021, 115, 438-446.	0.5	11
12	Assessing the impact of semen quality on embryo development in an egg donation model. F&S Reports, 2021, 2, 22-29.	0.4	4
13	Factors associated with worse cerebrovascular function in aging women with and at risk for HIV. Aids, 2021, 35, 257-266.	1.0	4
14	Predictors of adequate physical activity within a multiethnic polycystic ovary syndrome patient population: a cross-sectional assessment. BMC Women's Health, 2021, 21, 108.	0.8	2
15	Reproductive Endocrinology and Infertility fellowship programs: Does one size fit all?. Fertility and Sterility, 2021, 115, 569-575.	0.5	3
16	Uterine synechiae after intrauterine device use: a case series. Journal of Assisted Reproduction and Genetics, 2021, 38, 2625-2629.	1.2	2
17	Diminished ovarian reserve is associated with reduced euploid rates via preimplantation genetic testing for aneuploidy independently from age: evidence for concomitant reduction in oocyte quality with quantity. Fertility and Sterility, 2021, 115, 966-973.	0.5	36
18	Concomitant tamoxifen or letrozole for optimal oocyte yield during fertility preservation for breast cancer: the TAmoxifen or Letrozole in Estrogen Sensitive tumors (TALES) randomized clinical trial. Journal of Assisted Reproduction and Genetics, 2021, 38, 2455-2463.	1.2	8

#	Article	IF	CITATIONS
19	Effect of an Active vs Expectant Management Strategy on Successful Resolution of Pregnancy Among Patients With a Persisting Pregnancy of Unknown Location. JAMA - Journal of the American Medical Association, 2021, 326, 390.	3.8	15
20	Changing stimulation protocol on repeat conventional ovarian stimulation cycles does not lead to improved laboratory outcomes. Fertility and Sterility, 2021, 116, 757-765.	0.5	7
21	Association of obstructive sleep apnea risk with depression and anxiety symptoms in women with polycystic ovary syndrome. Journal of Clinical Sleep Medicine, 2021, 17, 2041-2047.	1.4	4
22	Autologous platelet-rich plasma treatment for moderate-severe Asherman syndrome: the first experience. Journal of Assisted Reproduction and Genetics, 2021, 38, 2955-2963.	1.2	10
23	Associations Between Anti-Mullerian Hormone and Cardiometabolic Health in Reproductive Age Women Are Explained by Body Mass Index. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e555-e563.	1.8	13
24	Polycystic ovary syndrome (PCOS) is associated with NASH severity and advanced fibrosis. Liver International, 2020, 40, 355-359.	1.9	50
25	Increased Body Mass Index Is Associated With A Nondilutional Reduction in Antim $\tilde{A}\frac{1}{4}$ llerian Hormone. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3234-3242.	1.8	22
26	Obesity and depression are risk factors for future eating disorder-related attitudes and behaviors in women with polycystic ovary syndrome. Fertility and Sterility, 2020, 113, 1039-1049.	0.5	16
27	Pregnancy registry: three-year follow-up of children conceived from letrozole, clomiphene, or gonadotropins. Fertility and Sterility, 2020, 113, 1005-1013.	0.5	7
28	Non-alcoholic fatty liver disease in pregnancy is associated with adverse maternal and perinatal outcomes. Journal of Hepatology, 2020, 73, 516-522.	1.8	78
29	The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and Sterility, 2020, 113, 552-560.e3.	0.5	126
30	Increasing NIH funding for academic departments of obstetrics and gynecology: a call to action. American Journal of Obstetrics and Gynecology, 2020, 223, 79.e1-79.e8.	0.7	18
31	Ovarian stimulation and egg retrieval in the acutely ill patient: special considerations. Journal of Assisted Reproduction and Genetics, 2019, 36, 2087-2094.	1.2	0
32	Ovarian stimulation for fertility preservation or family building in a cohort of transgender men. Journal of Assisted Reproduction and Genetics, 2019, 36, 2155-2161.	1.2	76
33	Impact of menopausal hormone formulations on pituitary-ovarian regulatory feedback. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2019, 317, R912-R920.	0.9	15
34	Depression Over the Lifespan in a Population-Based Cohort of Women With Polycystic Ovary Syndrome: Longitudinal Analysis. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2809-2819.	1.8	43
35	Back-to-back random-start ovarian stimulation prior to chemotherapy to maximize oocyte yield. Journal of Assisted Reproduction and Genetics, 2019, 36, 1161-1168.	1.2	16
36	Interpregnancy interval and singleton pregnancy outcomes after frozen embryo transfer. Fertility and Sterility, 2019, 111, 1145-1150.	0.5	4

#	Article	IF	Citations
37	The American Gynecological and Obstetrical Society—reinvigorating for the 21st century. American Journal of Obstetrics and Gynecology, 2019, 220, 365.e1-365.e3.	0.7	O
38	The Kronos Early Estrogen Prevention Study (KEEPS). Menopause, 2019, 26, 1071-1084.	0.8	97
39	Clinical course of depression symptoms and predictors of enduringÂdepression risk in women with polycystic ovary syndrome: Results of a longitudinal study. Fertility and Sterility, 2019, 111, 147-156.	0.5	28
40	Links between age at menarche, antral follicle count, and body mass index in African American and European American women. Fertility and Sterility, 2019, 111, 122-131.	0.5	7
41	Sex hormone levels by presence and severity of cirrhosis in women with chronic hepatitis C virus infection. Journal of Viral Hepatitis, 2019, 26, 258-262.	1.0	17
42	The efficiency of single institutional review board review in National Institute of Child Health and Human Development Cooperative Reproductive Medicine Network–initiated clinical trials. Clinical Trials, 2019, 16, 3-10.	0.7	13
43	Sex-Based Differences in Human Immunodeficiency Virus Type 1 Reservoir Activity and Residual Immune Activation. Journal of Infectious Diseases, 2019, 219, 1084-1094.	1.9	73
44	Ovarian aging is associated with gray matter volume and disability in women with MS. Neurology, 2018, 90, e254-e260.	1.5	41
45	A novel oocyte maturation trigger using 1500ÂIU of human chorionic gonadotropin plus 450ÂIU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols. Journal of Assisted Reproduction and Genetics, 2018, 35, 297-307.	1.2	9
46	Declining Fertility with Reproductive Aging. Obstetrics and Gynecology Clinics of North America, 2018, 45, 575-583.	0.7	2
47	Cardiovascular health and ovarian aging. Fertility and Sterility, 2018, 110, 790-793.	0.5	37
48	Decision-making surrounding the use of preimplantation genetic testing for aneuploidy reveals misunderstanding regarding its benefit. Journal of Assisted Reproduction and Genetics, 2018, 35, 2155-2159.	1,2	14
49	To freeze or not to freeze: decision regret and satisfaction following elective oocyte cryopreservation. Fertility and Sterility, 2018, 109, 1097-1104.e1.	0.5	83
50	Association among depression, symptom experience, and quality of life in polycystic ovary syndrome. American Journal of Obstetrics and Gynecology, 2018, 219, 279.e1-279.e7.	0.7	48
51	Insulin resistance is associated with depression risk in polycystic ovary syndrome. Fertility and Sterility, 2018, 110, 27-34.	0.5	47
52	Impact of the levonorgestrel-releasing intrauterine device on controlled ovarian stimulation outcomes. Fertility and Sterility, 2018, 110, 83-88.	0.5	13
53	The Association of Hispanic Ethnicity with Nonalcoholic Fatty Liver Disease in Polycystic Ovary Syndrome., 2018, 1, 24-33.		3
54	Testosterone Levels in Pre-Menopausal Women are Associated With Nonalcoholic Fatty Liver Disease in Midlife. American Journal of Gastroenterology, 2017, 112, 755-762.	0.2	49

#	Article	IF	CITATIONS
55	Women with polycystic ovary syndrome demonstrate worsening markers of cardiovascular risk over the shortâ€term despite declining hyperandrogenaemia: Results of a longitudinal study with community controls. Clinical Endocrinology, 2017, 87, 775-782.	1.2	19
56	Effects of Oral vs Transdermal Estrogen Therapy on Sexual Function in Early Postmenopause. JAMA Internal Medicine, 2017, 177, 1471.	2.6	59
57	Outcomes from a university-based low-cost inÂvitro fertilization program providing access to care for a low-resource socioculturally diverse urban community. Fertility and Sterility, 2017, 108, 642-649.e4.	0.5	14
58	Ageâ€stratified thresholds of antiâ€Müllerian hormone improve prediction of polycystic ovary syndrome over a populationâ€based threshold. Clinical Endocrinology, 2017, 87, 733-740.	1.2	26
59	Cancer survivors of gynecologic malignancies are at risk for decreased opportunity for fertility preservation. Contraception and Reproductive Medicine, 2017, 2, 12.	0.7	7
60	AntimÃ $\frac{1}{4}$ llerian hormone levels and antral follicle counts are not reduced compared with community controls in patients with rigorously defined unexplained infertility. Fertility and Sterility, 2017, 108, 1070-1077.	0.5	20
61	The sixth vital sign: what reproduction tells us about overall health. Proceedings from a NICHD/CDC workshop. Human Reproduction Open, 2017, 2017, hox008.	2.3	39
62	Raising threshold for diagnosis of polycystic ovary syndrome excludes population of patients with metabolic risk. Fertility and Sterility, 2016, 106, 1244-1251.	0.5	15
63	Fresh versus frozen: initial transfer or cumulative cycle results: how do we interpret results and design studies?. Fertility and Sterility, 2016, 106, 251-256.	0.5	19
64	Baseline AMH Level Associated With Ovulation Following Ovulation Induction in Women With Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3288-3296.	1.8	30
65	Vigorous exercise is associated with superior metabolic profiles in polycystic ovary syndrome independent of total exercise expenditure. Fertility and Sterility, 2016, 105, 486-493.	0.5	39
66	Dynamic secretion during meiotic reentry integrates the function of the oocyte and cumulus cells. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 2424-2429.	3.3	37
67	Assisted reproductive technology: moving forward—or just moving?. Fertility and Sterility, 2016, 105, 588-589.	0.5	1
68	Clinician vs Self-ratings of Hirsutism in Patients With Polycystic Ovarian Syndrome. JAMA Dermatology, 2016, 152, 783.	2.0	52
69	Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS–Cognitive and Affective Study. PLoS Medicine, 2015, 12, e1001833.	3.9	330
70	Introduction. Fertility and Sterility, 2015, 103, 1379-1380.	0.5	23
71	Who are we? A perspective on the reproductive endocrinologist and infertility specialist in the 21st century. Fertility and Sterility, 2015, 104, 26-27.	0.5	7
72	Fellowship training and board certification in reproductive endocrinology and infertility. Fertility and Sterility, 2015, 104, 3-7.	0.5	33

#	Article	IF	CITATIONS
73	Polycystic Ovary Syndrome: Special Diagnostic and Therapeutic Considerations for Children. Pediatric Dermatology, 2015, 32, 571-578.	0.5	12
74	Putative role for insulin resistance in depression risk in polycystic ovary syndrome. Fertility and Sterility, 2015, 104, 707-714.e1.	0.5	46
75	The KEEPS-Cognitive and Affective Study: Baseline Associations between Vascular Risk Factors and Cognition. Journal of Alzheimer's Disease, 2014, 40, 331-341.	1.2	25
76	Prevalence of androgenic alopecia in patients with polycystic ovary syndrome and characterization of associated clinical and biochemical features. Fertility and Sterility, 2014, 101, 1129-1134.	0.5	58
77	A novel "delayed start―protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders. Fertility and Sterility, 2014, 101, 1308-1314.	0.5	38
78	Introduction. Fertility and Sterility, 2014, 101, 885-886.	0.5	0
79	Contraceptionâ€"when did something so right go so wrong?. Fertility and Sterility, 2014, 102, 32-33.	0.5	2
80	National reporting of inÂvitro fertilization success rates: how do we get patients useful information?. Fertility and Sterility, 2013, 100, 1210-1211.	0.5	12
81	Does accelerated reproductive aging underlie premenopausal risk for cardiovascular disease?. Menopause, 2013, 20, 1139-1146.	0.8	59
82	Biomarkers of Ovarian Reserveâ€"Do They Predict Somatic Aging?. Seminars in Reproductive Medicine, 2013, 31, 443-451.	0.5	21
83	Diminished Ovarian Reserve. How Do You Diagnosis It? What Does It Mean?. Seminars in Reproductive Medicine, 2013, 31, 391-392.	0.5	2
84	Age-related differences in the reproductive and metabolic implications of polycystic ovarian syndrome: findings in an obese, United States population. Gynecological Endocrinology, 2012, 28, 819-822.	0.7	18
85	Genetic markers of ovarian follicle number and menopause in women of multiple ethnicities. Human Genetics, 2012, 131, 1709-1724.	1.8	60
86	Genetic variants and environmental factors associated with hormonal markers of ovarian reserve in Caucasian and African American women. Human Reproduction, 2012, 27, 594-608.	0.4	91
87	A characterization of the relationship of ovarian reserve markers with age. Fertility and Sterility, 2012, 97, 238-243.	0.5	108
88	The Role of Anti-MÃ $\frac{1}{4}$ llerian Hormone (AMH) in Assessing Ovarian Reserve. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3609-3614.	1.8	59
89	Oxidative Stress and Reproductive Capacity in Iron Overload Thalassemia Major Women. Blood, 2011, 118, 2155-2155.	0.6	0
90	Is antral follicle count a genetic trait?. Menopause, 2010, 17, 109-113.	0.8	15

#	Article	IF	CITATIONS
91	Fertilization rate is an independent predictor of implantation rate. Fertility and Sterility, 2010, 94, 1328-1333.	0.5	31
92	Antral follicle count: absence of significant midlife decline. Fertility and Sterility, 2010, 94, 2182-2185.	0.5	48
93	Luteal phase estrogen is decreased in regularly menstruating older women compared with a reference population of younger women. Menopause, 2008, 15, 482-486.	0.8	20
94	Triphasic oral contraceptives: review and comparison of various regimens. Fertility and Sterility, 2002, 77, 1-14.	0.5	25
95	Response Letter to the Editor From Kloos: "Evaluation of Female Fertility – AMH and Ovarian Reserve Testing― Journal of Clinical Endocrinology and Metabolism, 0, , .	1.8	O